Swedish biopharmaceutical company Hansa Medical has reported topline results from its Phase II study of IdeS for kidney transplantation.

Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) is an enzyme based on a novel mechanism specifically designed to cleave human IgG antibodies.

It inactivates human IgG antibodies, to prevent and treat patients who have developed pathogenic IgG.

The Phase II study involved ten patients administered with single doses of IdeS prior to kidney transplantation.

“The study is primarily focused on determining the safety and tolerability of IdeS within sensitised kidney transplantation patients.”

The study is primarily focused on determining the safety and tolerability of IdeS within sensitised kidney transplantation patients.

It is also aimed at determining the IdeS dose that leads to anti-HLA antibody levels acceptable for transplantation within 24 hours from dosing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The patients involved in the study were followed for six months after transplantation to assess the drug safety and kidney function.

Preliminary results suggested that IdeS has enabled kidney transplantation, resulting in a negative cross match test in all patients with no events of delayed graft function recorded.

All ten transplantations also resulted in good creatinine levels.

Hansa Medical is also conducting two other clinical studies with IdeS in sensitised patients, consisting of an investigator-initiated Phase II study at the Cedars-Sinai Medical Center in Los Angeles and a pivotal multicentre study in the US with IdeS in refractory, highly sensitised patients.